Glucotrack announces pricing of $10 million underwritten public offering of common stock

Rutherford, nj, april 13, 2023 (globe newswire) -- glucotrack, inc. (nasdaq: gctk) (“glucotrack” or the “company”), a medical device and digital health platform company focused on diabetes and prediabetes, today announced the pricing of a firm commitment underwritten public offering of shares of its common stock with gross proceeds to the company expected to be approximately $10 million, before deducting underwriting discounts and other estimated expenses payable by the company. the offering consists of 7,352,942 shares of common stock and pre-funded warrants at a price to the public of $1.36 per share (less $0.001 in exercise price per pre-funded warrant). the company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, which may include, without limitation, engaging in acquisitions or other business combinations or investments, sales and marketing activities, general and administrative matters and capital expenditures.
GCTK Ratings Summary
GCTK Quant Ranking